Arena Pharma (ARNA) Dips; Enrollment Accelerated for Orexigen's (OREX) Contrave Trial
Tweet
Share
E-mail
Get Alerts ARNA Hot Sheet
Join SI Premium – FREE
Arena Pharmaceuticals (Nasdaq: ARNA) is indicated lower Wednesday morning following a release from peer Orexigen (Nasdaq: OREX) that enrollment in the Light Study, the Contrave cardiovascular outcomes clinical trial, is going faster than expected.
Arena is bid about 2.8 percent lower.
Otherwise, VIVUS (Nasdaq: VVUS), which has its Qnexa slated for an upcoming PDUFA date with the FDA, is also bid slightly lower ahead of the bell.
For more color from Orexigen, click here.
Arena is bid about 2.8 percent lower.
Otherwise, VIVUS (Nasdaq: VVUS), which has its Qnexa slated for an upcoming PDUFA date with the FDA, is also bid slightly lower ahead of the bell.
For more color from Orexigen, click here.
Create E-mail Alert Related Categories
FDA, Insiders' Blog, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
